IPHA_logo_main_version_h100IPHA_logo_main_version_h100IPHA_logo_main_version_h100IPHA_logo_main_version_h100
  • Home
  • #InnovateForLife
  • News
  • Events
    • IPHA Forum
    • IPHA Conference
    • All other events
  • Publications
    • 2025
      • Industry’s Role in Shaping Ireland’s Life Science Strategy
      • EFPIA Patients Wait Indicator 2024
      • IPHA Position Paper on Fairer and Faster Access to Medicine
    • 2024
      • EFPIA Patient WAIT Indicator Survey
      • Clinical Trials Agreement
      • Making Ireland a European Leader in Clinical Research
    • 2023
      • Achieving Universal Access to New Medicines for Irish Patients
      • Oireachtas briefing
      • IPHA Policy on Supply Outside Reimbursement Final
      • IPHA Self-Care Infographic
    • 2022
      • IPHA reimbursement timelines analysis 2022
      • Factors Affecting the Location of Biopharmaceutical Investments and Implications for European Policy Priorities
      • IHE Cancer Care Comparator Study
      • White Paper on Enterprise
    • 2021
      • Clinical Trials Survey
      • Cell and Gene Pathfinder Study
      • IPHA Codes of Practice
      • Agreement 2021
    • Pre 2020
      • BioPharma Ambition
      • Manifesto for Better Health
      • Innovation and the IP Framework
      • Self-Care: Taking Charge of Your Health
      • Vaccines For Life
      • Perspectives on Ireland’s Medicines Future
  • Submissions
    • 2025
      • IPHA Life Science Strategy Submission Dec 25
      • IPHA Response LSS Consultation final 25
      • RD Incentives Consulation_Final 19 May 25
    • 2024
      • IPHA Submission National Rare Disease Strategy 2024
    • 2023
      • Expert Taskforce Submission September 2023 letter
      • Sinn Fein consultation paper Dec 23
  • Code
    • Codes of Practice
    • Transfers of Value
    • Mandatory notification regarding Advisory Board Meetings
    • IPHA Code Training
    • Complaints
  • Clinical & Regulatory
    • Regulation for Innovation
    • Clinical Trials
    • Medicine Safety
    • Regulatory Science Ireland
    • Counterfeit Medicines
  • Self-Care
  • About
    • Members
    • Board of Directors
    • Media Queries
    • Our Team
    • Affiliates Programme
    • Job Opportunities
  • Home
  • #InnovateForLife
  • News
  • Events
    • IPHA Forum
    • IPHA Conference
    • All other events
  • Publications
    • 2025
      • Industry’s Role in Shaping Ireland’s Life Science Strategy
      • EFPIA Patients Wait Indicator 2024
      • IPHA Position Paper on Fairer and Faster Access to Medicine
    • 2024
      • EFPIA Patient WAIT Indicator Survey
      • Clinical Trials Agreement
      • Making Ireland a European Leader in Clinical Research
    • 2023
      • Achieving Universal Access to New Medicines for Irish Patients
      • Oireachtas briefing
      • IPHA Policy on Supply Outside Reimbursement Final
      • IPHA Self-Care Infographic
    • 2022
      • IPHA reimbursement timelines analysis 2022
      • Factors Affecting the Location of Biopharmaceutical Investments and Implications for European Policy Priorities
      • IHE Cancer Care Comparator Study
      • White Paper on Enterprise
    • 2021
      • Clinical Trials Survey
      • Cell and Gene Pathfinder Study
      • IPHA Codes of Practice
      • Agreement 2021
    • Pre 2020
      • BioPharma Ambition
      • Manifesto for Better Health
      • Innovation and the IP Framework
      • Self-Care: Taking Charge of Your Health
      • Vaccines For Life
      • Perspectives on Ireland’s Medicines Future
  • Submissions
    • 2025
      • IPHA Life Science Strategy Submission Dec 25
      • IPHA Response LSS Consultation final 25
      • RD Incentives Consulation_Final 19 May 25
    • 2024
      • IPHA Submission National Rare Disease Strategy 2024
    • 2023
      • Expert Taskforce Submission September 2023 letter
      • Sinn Fein consultation paper Dec 23
  • Code
    • Codes of Practice
    • Transfers of Value
    • Mandatory notification regarding Advisory Board Meetings
    • IPHA Code Training
    • Complaints
  • Clinical & Regulatory
    • Regulation for Innovation
    • Clinical Trials
    • Medicine Safety
    • Regulatory Science Ireland
    • Counterfeit Medicines
  • Self-Care
  • About
    • Members
    • Board of Directors
    • Media Queries
    • Our Team
    • Affiliates Programme
    • Job Opportunities
  • Home
  • About Us
  • Contact Us

Membership

  • Home
  • About Us
  • Membership
The IPHA represents the international research-based pharmaceutical industry in Ireland and comprises of member companies who are responsible for developing, manufacturing and bringing innovative medicines to Irish patients. For further information on our members, please click on company name below:

A Menarini Pharmaceuticals Ireland Ltd


AbbVie Limited


Alliance Pharmaceuticals Ireland


Almirall Ltd


Alimera Sciences Europe Limited


Amgen Ireland Limited


Astellas Pharma Ltd


Bayer Consumer Health *


Bayer Limited


Biogen Idec (Ireland) Ltd


Boehringer Ingelheim Ireland Limited


Bristol-Myers Squibb Pharmaceuticals uc


Chugai Pharma UK Ltd


Daiichi Sankyo Ireland Ltd.


Eisai Limited


Eli Lilly & Company (Ireland) Ltd


Gilead Sciences Ireland UC


GlaxoSmithKline


Haleon *


Ipsen Pharmaceuticals Limited


Johnson & Johnson Innovative Medicine


Jazz Pharmaceuticals


LEO Pharma


Lundbeck (Ireland) Ltd


Merck


MSD


Mundipharma Pharmaceuticals Company


Novartis Ireland Ltd


Novo Nordisk Limited


Kenvue*


Organon Pharma BV


Otsuka Pharmaceuticals (UK) Ltd


Perrigo *


Pfizer Healthcare Ireland


Reckitt *


Roche Products (Ireland) Limited


Sanofi Ltd


Servier Laboratories (Ireland) Limited


Takeda Products Ireland Ltd.


Tillotts Pharma Ltd


UCB

 

* Self-Care Division

Terms and Conditions    |    Privacy Statement   |   Sitemap    |    Cookies


Registered Number: 254776    |    Registered Address: 7 Clanwilliam Terrace, Dublin 2, D02 CC64 Ireland   |  Email: info@ipha.ie

© 2024 IPHA